Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Ter Heine

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Nuclear Medicine Communications|February 4, 2015
Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approachRogier Lange, Rob ter Heine, Clemens Decristoforo, et al.
Clinical Pharmacokinetics|June 20, 2018
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge GapsRuben van der Galiën, Rob Ter Heine, Rick Greupink, et al.
Journal of Pharmaceutical Sciences|April 15, 2011
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavirRob ter Heine, Robert A B Van Waterschoot, Ron J Keizer, et al.
Scandinavian Journal of Infectious Diseases|May 14, 2011
Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literatureMilly E Haverkort, Bas W van der Spek, Paul Lips, et al.
British Journal of Clinical Pharmacology|September 21, 2021
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patientsSimon E Koele, Stijn W van Beek, Anthonie J van der Wekken, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patientsRob Ter Heine, Jan Willem Mulder, Eric C M van Gorp, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2017
Age, Weight, and <i>CYP2D6</i> Genotype Are Major Determinants of Primaquine Pharmacokinetics in African ChildrenBronner P Gonçalves, Helmi Pett, Alfred B Tiono, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 21, 2021
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation StudyLucas E Hermans, Monique Nijhuis, Hugo A Tempelman, et al.
International Immunopharmacology|May 3, 2025
Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionalityJudith D J Verdonk, Berber Piet, Rob Ter Heine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumorsRoos L Oostendorp, Alwin Huitema, Hilde Rosing, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Nuclear Medicine Communications|February 4, 2015
Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approachRogier Lange, Rob ter Heine, Clemens Decristoforo, et al.
Clinical Pharmacokinetics|June 20, 2018
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge GapsRuben van der Galiën, Rob Ter Heine, Rick Greupink, et al.
Journal of Pharmaceutical Sciences|April 15, 2011
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavirRob ter Heine, Robert A B Van Waterschoot, Ron J Keizer, et al.
Scandinavian Journal of Infectious Diseases|May 14, 2011
Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literatureMilly E Haverkort, Bas W van der Spek, Paul Lips, et al.
British Journal of Clinical Pharmacology|September 21, 2021
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patientsSimon E Koele, Stijn W van Beek, Anthonie J van der Wekken, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patientsRob Ter Heine, Jan Willem Mulder, Eric C M van Gorp, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2017
Age, Weight, and <i>CYP2D6</i> Genotype Are Major Determinants of Primaquine Pharmacokinetics in African ChildrenBronner P Gonçalves, Helmi Pett, Alfred B Tiono, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 21, 2021
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation StudyLucas E Hermans, Monique Nijhuis, Hugo A Tempelman, et al.
International Immunopharmacology|May 3, 2025
Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionalityJudith D J Verdonk, Berber Piet, Rob Ter Heine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumorsRoos L Oostendorp, Alwin Huitema, Hilde Rosing, et al.
Pageof 16